Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mashael Hakami"'
Autor:
Sumaiah J. Alarfaj, Abdullah Alzahrani, Anfal Alotaibi, Malak Almutairi, Mashael Hakami, Njood Alhomaid, Noori Alharthi, Ghazwa B. Korayem, Abdullah Alghamdi
Publikováno v:
Saudi Pharmaceutical Journal, Vol 30, Iss 10, Pp 1448-1453 (2022)
Background: The introduction of direct-acting antivirals (DAA) to treat the hepatitis C virus (HCV) overcame many drawbacks of interferon-based therapy. DAA achieved sustained viral response (SVR) rates above 90% and overcame many drawbacks of pegyla
Externí odkaz:
https://doaj.org/article/4db795d0143a47a5b615be8755be57ef
Autor:
Abdulaziz Alhazmi, Edrous Alamer, Dalia Daws, Mashael Hakami, Majid Darraj, Siddig Abdelwahab, Amani Maghfuri, Abdullah Algaissi
Publikováno v:
Vaccines, Vol 9, Iss 6, p 674 (2021)
Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term pos
Externí odkaz:
https://doaj.org/article/06c78b02409f4c9d8a35bcd1da5566ec
Autor:
Dalia Daws, Majid Darraj, Edrous Alamer, Siddig Ibrahim Abdelwahab, Mashael Hakami, Amani Maghfuri, Abdulaziz Alhazmi, Abdullah Algaissi
Publikováno v:
Vaccines, Vol 9, Iss 674, p 674 (2021)
Vaccines
Volume 9
Issue 6
Vaccines
Volume 9
Issue 6
Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f89250be6c261d9f660c43ebaa6523d
https://pubmed.ncbi.nlm.nih.gov/34207394
https://pubmed.ncbi.nlm.nih.gov/34207394